Inhibition of CDK6 may prevent arteriovenous malformations in hereditary hemorrhagic telangiectasia by regulating endothelial ...

The FDA recently approved the combination of inavolisib, fulvestrant, and palbociclib in this patient population.

With newer breast cancer treatments, it’s essential that nurses and APPs educate themselves and advocate for their patients.

A new drug combination could double survival time for advanced breast cancer patients. Researchers have developed a therapy ...

A powerful three-drug combination for aggressive advanced breast cancer doubles the length of time before the cancer progresses, compared with a drug combination currently available on the NHS, new ...

THURSDAY, Oct. 31, 2024 (HealthDay News) -- Inavolisib plus palbociclib-fulvestrant yields significantly longer ...

Roche (RHHBY) announced that a detailed analysis of the positive phase III INAVO120 results, evaluating Itovebi in combination with palbociclib ...

CIDRAP: Paxlovid Tied To Fewer COVID-19 Hospitalizations, Reduced Risk Of Long COVID A new retrospective cohort study conducted in Dubai shows that the antiviral nirmatrelvir plus ritonavir, ...

Swiss pharma giant Roche has released detailed analysis of the positive Phase III INAVO120 results, evaluating Itovebi (inavolisib) in combination with palbociclib (Ibrance) and fulvestrant were ...

Among these participants, 161 received a three-drug therapy comprising two targeted drugs, palbociclib (a cancer growth ...